Osavampator - Takeda
Alternative Names: NBI 1065845; NBI-845; TAK 653Latest Information Update: 15 Jul 2025
At a glance
- Originator Takeda
- Developer Neurocrine Biosciences; Takeda
- Class Antidepressants; Small molecules
- Mechanism of Action AMPA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- No development reported Depressive disorders
Most Recent Events
- 30 May 2025 Phase-III clinical trials in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT06963021)
- 11 May 2025 Neurocrine Biosciences plans a phase III trial for Major Depressive Disorder in Unknown location (PO, Tablet) in May 2025 (NCT06966401)
- 08 May 2025 Neurocrine Biosciences plans a phase-III trial for Major depressive disorders (Adjunctive treatment) in May 2025 (PO) (NCT06963021)